Budesonide, glycopyrrolate and formoterol

The current U.S. 04/2026 label covers maintenance COPD treatment in adults and maintenance asthma treatment in adults/adolescents age 12 and older. COPD uses 160/9/4.8 mcg per inhalation; asthma uses 160/18/4.8 mcg. The order is budesonide/glycopyrrolate/formoterol fumarate. Older COPD-only statements are superseded for this current product, but the two strengths are not automatically interchangeable.

Breztri is a prescription metered-dose inhaler approved under NDA 212122. It is not indicated for acute bronchospasm, and primary treatment of status asthmaticus or acute episodes needing intensive measures is contraindicated. Formoterol’s rapid onset does not make this triple product a rescue/MART inhaler. Label COPD and asthma trial benefits are population-specific; no universal risk-reduction or first-line claim is inferred.

Take two inhalations in the morning and two in the evening by oral inhalation; never exceed two inhalations twice daily. The table distinguishes each puff from each TWO-PUFF administration. Rinse the mouth with water after each two-puff administration and spit rather than swallow. Do not add extra Breztri doses for symptoms.

Prime a new inhaler with four test sprays into the air away from the face, shaking before each. Re-prime with two sprays after more than seven days unused, if dropped, or after weekly actuator rinsing. Use the matching Breztri actuator and follow the illustrated inhalation sequence in the actual pack. Shake before each puff; coordinate actuation with a slow deep breath and hold as instructed. Test sprays are not treatment inhalations.

For the 120-inhalation device, rinse the yellow actuator weekly after removing/keeping the metal canister dry. The FDA illustrated instructions specify 30 seconds warm-water rinsing through the mouthpiece and 30 through the actuator top, then air-dry fully, such as overnight; do not towel-dry or reinsert the canister while wet. Re-prime with two test sprays after reassembly. Follow the actual 28-puff institutional device leaflet, which differs in illustrated cleaning content. Replace when the indicator reaches zero; residual canister contents do not guarantee a full dose.

Patient Information directs taking a missed dose as soon as remembered, but not more than two inhalations twice daily. Do not double or use extra maintenance doses as rescue. Have the prescribed acute-relief inhaler and action plan: current label describes a short-acting beta-agonist/corticosteroid option for asthma or a short-acting beta agonist for asthma/COPD. Increased rescue need or declining benefit requires prompt reassessment.

No older-age-only adjustment is necessary in the label, although sensitivity can vary. Severe hepatic disease requires close monitoring. At the label’s severe-renal threshold, or dialysis, use only when expected benefit outweighs risk; no numerical reduced-puff regimen is established. Taper prior systemic corticosteroids slowly under supervision and monitor lung function/rescue use and adrenal symptoms. Breztri does not supply the systemic steroid support needed during adrenal stress.

Contraindicated for primary treatment of status asthmaticus or other acute COPD/asthma episodes requiring intensive measures, and with hypersensitivity to any active ingredient or excipient. Narrow-angle glaucoma, urinary retention and severe organ disease are separate cautions/benefit-risk restrictions, not automatically the same formal contraindication category.

The current selected Breztri label has no formal boxed warning. It contains a serious asthma-event warning distinguishing LABA monotherapy from ICS/LABA therapy, plus important acute-deterioration, adrenal, infection and cardiovascular precautions. No absence-of-risk conclusion follows from boxed-warning status.

COPD trials report respiratory infections, pneumonia, back pain, oral candidiasis, influenza, muscle spasms, urinary infection, cough, sinusitis, diarrhea and dysphonia. Current asthma trials commonly report nasopharyngitis, pneumonia and headache. Component-associated reports also include palpitations, tremor, dry mouth, urinary retention and steroid effects. Trial frequencies from one indication/strength are not universal rates for the other.

Strong CYP3A4 inhibitors such as ritonavir, ketoconazole, itraconazole or clarithromycin can increase budesonide exposure and systemic steroid effects. Use caution and individualize therapy/monitoring; the label does not supply a universal dose reduction or automatic safe combination. Review even short-course new medicines.

Additional adrenergic agents can potentiate formoterol effects; do not add another LABA. Xanthines, systemic steroids and diuretics can worsen hypokalemia; non-potassium-sparing diuretics can add ECG effects. MAO inhibitors, tricyclics and QT-prolonging drugs require extreme caution for cardiovascular effects. Check clinically appropriate potassium/ECG when risk warrants rather than routinely supplement every patient.

Beta blockers can oppose bronchodilation and cause severe bronchospasm; generally avoid, while essential cardiac indications may require carefully selected cardioselective therapy. Include timolol eye drops in the actual medication history. Avoid other anticholinergic-containing medicines because urinary/ocular and other effects can add; do not independently stop prescribed emergency medicines without an action plan.

Asthma use is established from age 12; below 12 safety/effectiveness are not established. ICS can reduce growth velocity, so monitor growth routinely and weigh long-term treatment benefits. Older patients need no routine age-only adjustment, but greater sensitivity cannot be excluded and comorbid cardiac/urinary/bone/ocular risks matter.

Formal combination PK studies in renal/hepatic impairment were not performed. At severe renal impairment, labeled creatinine clearance ≤ 30 mL/min/1.73 m², or dialysis, use only if expected benefit exceeds risk. This is the label’s indexed wording, not an independently validated universal eGFR interchange. Severe liver disease may increase budesonide/formoterol exposure; monitor closely. No alternate-day or half-puff algorithm is established.

Combination, glycopyrrolate and formoterol human data are inadequate; inhaled-budesonide observational data are more reassuring but do not prove the triple product risk-free. Poor asthma control also increases maternal/fetal risk; monitor and individualize therapy. During labor beta-agonist effects can interfere with uterine contractility, so use only when benefit clearly outweighs risk. Do not independently stop controller therapy for pregnancy.

Budesonide is present in human milk; human milk information for glycopyrrolate/formoterol and effects on infant/milk production is lacking. Assess maternal respiratory-treatment needs, feeding benefits and infant circumstances. Budesonide-alone findings do not establish absence of exposure or universal safety for all three components.

Budesonide is an inhaled glucocorticoid with anti-inflammatory effects. Glycopyrrolate is a long-acting muscarinic antagonist, reducing M3-mediated airway smooth-muscle contraction. Formoterol is a long-acting beta 2 agonist producing bronchodilation. These complementary actions do not establish a reliever or universal step-up strategy for every patient.

After inhalation, label plasma peaks occur about 20–40 minutes for budesonide, 2–6 minutes for glycopyrrolate and 20–90 minutes for formoterol. COPD population-analysis effective half-lives are approximately five, 15 and 10 hours, respectively; they are not a validated redosing schedule or universal asthma/organ-disease estimate. Budesonide is extensively CYP3A4-metabolized, formoterol has hepatic conjugation/oxidative pathways and glycopyrronium clearance is substantially renal.

ETHOS/KRONOS support selected COPD lung-function/exacerbation findings; KALOS/LOGOS support current asthma maintenance approval. Regimens, comparison arms and study populations differ. Do not infer that the doubled glycopyrrolate asthma strength is superior for every COPD patient, or that old trial notation listing 320/18/9.6 mcg per two-puff COPD dose describes the new 160/18/4.8 mcg per-puff asthma inhaler.

Assess symptoms, exacerbations, lung function when appropriate, adherence, device technique and rescue use. Check thrush/infection, cardiovascular or urinary/ocular symptoms and adrenal effects. COPD label recommends baseline and periodic bone-density assessment; monitor pediatric growth and relevant eye/bone risks. Potassium/glucose or cardiac testing is risk-directed, not a mandatory universal fixed panel/interval.

Use the correct strength morning/evening, rinse/spit afterward, prime/re-prime and follow the pack-specific cleaning/discard rules. Keep the prescribed reliever/action plan available. Seek immediate care for serious breathing deterioration, paradoxical bronchospasm, severe allergy, acute painful red eye/halos or concerning cardiac symptoms. Contact the clinician for increased reliever need, pneumonia symptoms, thrush or urinary problems.

Do not independently stop maintenance treatment or substitute another inhaler’s actuator. Check for duplicate LABA/LAMA products and CYP3A4 inhibitors. Patients transitioning from systemic steroids require a taper and stress-supplementation plan; carry the clinician-recommended warning information. A controlled cough or better spirometry does not by itself prove adrenal recovery.

Current 120-inhalation COPD pack 160/9/4.8 mcg is NDC 0310-4616-12; asthma 160/18/4.8 mcg is NDC 0310-6616-01. Each has 10.7 g fill, a yellow actuator, white mouthpiece, grey cap and attached dose indicator. Verify the printed strength/indication rather than color alone. Each canister belongs only with its Breztri actuator.

Current strengths are 160/9/4.8 and 160/18/4.8 mcg per inhalation, ordered budesonide/glycopyrrolate/formoterol fumarate. Each two-puff administration doubles those amounts, not the number of daily administrations. Both have 120-puff packs and 28-puff institutional packs; no nebulizer or dry-powder conversion is supplied. PK active-moiety names glycopyrronium/formoterol do not silently redefine the labeled strength units.

Store 20–25°C with 15–30°C excursions, dry and away from heat/sunlight. Keep canister at room temperature before use; do not puncture, burn or expose above 49°C. Never use a float test. Discard at indicator zero OR three months after pouch removal for 120 puffs, three weeks for 28 puffs, whichever comes first. Record pouch-opening date; leftover contents do not extend usable dosing. Keep canister dry during actuator cleaning.